FrancophonIA/ELRC3.0 huggingface dataset:
English: • joint or muscle pain
Estonian: • liigese- või lihasevalu;
English: Visual disturbance adverse reactions have occurred in patients treated with Alunbrig (see section 4.8).
Estonian: Alunbrigiga ravitud patsientidel on esinenud kõrvaltoimetena nägemishäireid (vt lõik 4.8).
English: Day 1 to Day 7
Estonian: 1. aste
English: Table 2: Recommended Alunbrig dose modifications for adverse reactions Adverse reaction Severity*
Estonian: Soovitused Alunbrigi annuse muutmiseks kõrvaltoimete korral Kõrvaltoime
English: Bradycardia In ALTA, bradycardia was reported in 4.5% of patients treated with Alunbrig at the 180 mg regimen.
Estonian: Uuringus ALTA tekkis bradükardia 4,5%-l Alunbrigiga ravitud patsientidest, kellel kasutati 180 mg raviskeemi.
English: • Alunbrig should be permanently discontinued in case of recurrence.
Estonian: • Kordumise korral tuleb Alunbrigi kasutamine lõplikult lõpetada.
English: Film-coated tablets 28 film-coated tablets
Estonian: RAVIMVORM JA PAKENDI SUURUS Õhukese polümeerikattega tabletid 28 õhukese polümeerikattega tabletid
English: Inform your doctor of any visual disturbance that occurs during treatment, such as seeing flashes of light, blurry vision or light hurting your eyes.
Estonian: Ükskõik millise nägemishäire (nagu nt valgussähvatuste nägemine, nägemise hägustumine või silmade valgustundlikkus) tekkimisel ravi ajal teatage sellest oma arstile.
English: Round wide mouth high density polyethylene (HDPE) bottles with two-piece polypropylene child resistant screw cap with foil induction seal liner closures, containing either 7 or 30 film-coated tablets, together with one HDPE canister containing a molecular sieve desiccant.
Estonian: Pudelid sisaldavad 7 või 30 õhukese polümeerikattega tabletti ja ühte HDPE mahutit, milles on molekulaarsõelana toimiv desikant.
English: Common Memory impairment Dysgeusia
Estonian: Mälu halvenemine Düsgeusia
English: Very common Insomnia
Estonian: Väga sage Hüpertensioon
English: 90 mg regimen* (N = 26)
Estonian: Ravieelsete mõõdetavate aju metastaasidega patsiendid 90 mg raviskeem* (N = 26)
English: Dose reduction for hypertension occurred in 0.9% at the 180 mg regimen.
Estonian: 0,9%-l patsientidest, kellel kasutati 180 mg raviskeemi.
English: Fatigueo
Estonian: Väsimuso
English: • musculoskeletal chest pain
Estonian: • lihas-skeleti valu rindkeres;
English: • Alunbrig 180 mg film-coated tablets 3 plastic foil strips (blisters), containing 21 film-coated tablets
Estonian: 3 plastfooliumriba (blister), milles on 21 õhukese polümeerikattega tabletti
English: Alunbrig 180 mg film-coated tablets brigatinib
Estonian: RAVIMPREPARAADI NIMETUS Alunbrig 180 mg õhukese polümeerikattega tabletid brigatiniib
English: • Alunbrig 90 mg: 7 or 30 film-coated tablets
Estonian: • Alunbrig 90 mg: 7 või 30 õhukese polümeerikattega tabletti • Alunbrig 180 mg: 30 õhukese polümeerikattega tabletti
English: Alunbrig 90 mg film-coated tablets brigatinib
Estonian: RAVIMPREPARAADI NIMETUS Alunbrig 90 mg õhukese polümeerikattega tabletid brigatiniib
English: However, the study had weaknesses.
Estonian: Uuringul oli siiski puudusi.
English: It was first made available in Germany in the 1950s and subsequently in Austria and Hungary.
Estonian: Esimest korda toodi see turule Saksamaal 1950. aastatel ning seejärel Austrias ja Ungaris.
English: • If you have any questions or concerns, speak with a pharmacist or your doctor.
Estonian: • Kui teil on küsimusi või probleeme, rääkige oma arsti või apteekriga.
English: • An observational study involving adolescents and children aged over 4 years did not provide sufficient evidence of efficacy and safety in children and adolescents.
Estonian: • Noorukite ja üle 4-aastaste laste vaatlusuuringu ei tõendanud piisavalt efektiivsust ja ohutust lastel ja noorukitel.
English: The CHMP recommendation was sent to the European Commission which issued a legally binding decision valid throughout the EU.
Estonian: Inimravimite komitee soovitus edastati Euroopa Komisjonile, kes tegi kogu Euroopa Liidus kehtiva õiguslikult siduva otsuse.
English: The CHMP opinion was forwarded to the European Commission, which issued a final legally binding decision applicable in all EU Member States on 28/08/2017.
Estonian: Inimravimite komitee arvamus edastati Euroopa Komisjonile, kes tegi 28. augustil 2017 õiguslikult siduva lõpliku otsuse, mida kohaldatakse kõigis Euroopa Liidu liikmesriikides.
English: The data included clinical studies, scientific publications, post-marketing experience, as well as information provided by the company and the views of an expert group formed for evaluating Symbioflor 2.
Estonian: Sealhulgas vaadati läbi kliinilistest uuringutest, teadusväljaannetest ja turustamisjärgsetest kogemustest saadud andmed, samuti ettevõtte esitatud teave ja ravimi Symbioflor 2 hindamise eksperdirühma arvamused.
English: Medicines containing Escherichia coli are available as oral drops in Austria, Germany and Hungary under the following invented names: Symbioflor 2, Symbioflor E. Coli and Symbioflor Escherichia.
Estonian: Escherichia coli baktereid sisaldavaid ravimeid turustatakse Austrias, Saksamaal ja Ungaris suukaudsete tilkadena järgmiste nimetuste all: Symbioflor 2, Symbioflor E. Coli ja Symbioflor Escherichia.
English: Submission of the study report to national authorities will be a condition for maintaining Symbioflor 2's marketing authorisation.
Estonian: Uuringu aruande esitamine riiklikule pädevale asutusele on ravimi Symbioflor 2 müügiloa säilitamise tingimus.
English: • The safety profile of Symbioflor 2 is acceptable.
Estonian: • Ravimi Symbioflor 2 ohutusprofiili peetakse vastuvõetavaks.
English: On 22 June 2017 a review by European Medicines Agency (EMA) concluded that Symbioflor 2 and associated names can continue to be used for treatment of irritable bowel syndrome (IBS) in adults.
Estonian: 22. juunil 2017 järeldas Euroopa Ravimiamet (EMA) ravimiteabe läbivaatamise tulemusena, et ravimit Symbioflor 2 ja sarnaseid nimetusi tohib ka edaspidi kasutada soole ärritussündroomi raviks täiskasvanutel.
English: In reaching its conclusions, EMA's Committee for Medicinal Products for Human Use (CHMP) reviewed all available evidence on the effectiveness and safety of Symbioflor 2.
Estonian: Järelduste tegemisel vaatas EMA inimravimite komitee läbi kõik kättesaadavad tõendid ravimi Symbioflor 2 efektiivsuse ja ohutuse kohta.
English: • Speak with a pharmacist or your doctor if your symptoms of irritable bowel syndrome do not improve with Symbioflor 2 or if they get worse.
Estonian: • Pidage nõu oma arsti või apteekriga, kui soole ärritussündroomi sümptomid ravimiga Symbioflor 2 ei parane või kui sümptomid süvenevad.
English: It is marketed in some European Union countries for treating irritable bowel syndrome, functional gastrointestinal diseases and some other gastrointestinal disorders and for regulating the immune system.
Estonian: Ravimit turustatakse mõnes Euroopa Liidu liikmesriigis soole ärritussündroomi, seedetrakti funktsionaalhäirete ja seedetrakti mõne muu häire raviks ning immuunsüsteemi reguleerimiseks.
English: Symbioflor 2 and associated names contains Escherichia coli bacteria some of which have been broken down (autolysed) while others are living.
Estonian: Symbioflor 2 ja sarnased nimetused sisaldavad Escherichia coli baktereid, millest osa on lagundatud (autolüüsitud) ja osa elusbakterid.
English: Available evidence suggests that the risk of harm from Symbioflor 2 is low.
Estonian: Kättesaadavate tõendite kohaselt on ravimi Symbioflor 2 risk väike.
English: Since the available data were not sufficiently robust for the CHMP to draw conclusions on how well Symbioflor 2 works and whether it is effective for any particular type of IBS, the CHMP has asked the company to carry out a well-designed study on effectiveness and safety among patients with different features of IBS (e.g. those with diarrhoea or with constipation as an important feature).
Estonian: Et kättesaadavad andmed ei olnud piisavalt usaldusväärsed, et inimravimite komitee saanuks teha järeldusi ravimi Symbioflor 2 üldise efektiivsuse ja efektiivsuse kohta soole ärritussündroomi eri alavormide korral, palus komitee ettevõttel korraldada hästi kavandatud ülesehitusega uuringu ravimi efektiivsuse ja ohutuse kohta soole ärritussündroomi eri alavormidega patsientidel (nt kõhulahtisusega või kõhukinnisusega vorm).
English: Escherichia coli bacteria form part of the normal gut flora.
Estonian: Escherichia coli bakterid esinevad normaalses sooleflooras.
English: The way it works in irritable bowel syndrome is not fully understood.
Estonian: Ravimi toimemehhanism soole ärritussündroomi korral ei ole täielikult teada.
English: The company that markets Symbioflor 2 did not submit data to support its use in ‘functional gastrointestinal disorders' and agreed to remove this use from the medicine's authorisation.
Estonian: Ravimi Symbioflor 2 turustaja ei esitanud andmeid, mis oleksid toetanud ravimi kasutamist seedetrakti funktsionaalhäirete näidustusel, ning nõustus, et see näidustus eemaldatakse ravimi müügiloast.
English: The review of Symbioflor 2 (and associated names) was initiated on 30 March 2016 at the request of Germany, under Article 31 of Directive 2001/83/EC.
Estonian: 30. märtsil 2016 algatati Saksamaa taotlusel ravimi Symbioflor 2 (ja sarnaste nimetuste) direktiivi 2001/83/EÜ artikli 31 kohane hindamine.
English: However, the study had some weaknesses and it did not provide evidence on how well Symbioflor 2 works in different types of IBS.
Estonian: Uuringus oli siiski puudusi ja see ei tõendanud ravimi Symbioflor 2 efektiivsust soole ärritussündroomi eri alavormide korral.
English: Benefit has not yet been established in children with IBS.
Estonian: Ravimi kasulikkust soole ärritussündroomiga lastel ei ole veel tõendatud.
English: The review did not find any new evidence on the effectiveness of Symbioflor 2 since the product was last approved.
Estonian: Läbivaatamisel leiti, et ravimi Symbioflor 2 efektiivsuse kohta ei ole alates ravimi viimasest heakskiitmisest lisandunud uusi tõendeid.
English: • Speak with a pharmacist or your doctor if you have any problems affecting your stomach or gut.
Estonian: • Rääkige arstile või apteekrile, kui teil on mao- või sooleprobleeme.
English: • The product information will be updated in line with this review of Symbioflor 2.
Estonian: • Ravimiteavet ajakohastatakse ravimi Symbioflor 2 ravimiteabe käesoleva läbivaatamise tulemuste kohaselt.
English: The medicine has been described as probiotic, which means that it encourages the growth of beneficial organisms (‘flora') in the gut.
Estonian: Ravim on probiootikum ehk ravim, mis toetab kasulike soolebakterite (soolefloora) kasvu.
English: • You can continue to take Symbioflor 2 for treating symptoms of irritable bowel syndrome by following the information in the medicine's revised package leaflet.
Estonian: • Tohite jätkata ravimi Symbioflor 2 kasutamist soole ärritussündroomi sümptomite raviks, järgides uuel pakendi infolehel olevaid juhiseid.
English: • A study comparing Symbioflor 2 with placebo suggested that it was effective at treating IBS in adults.
Estonian: • Uuringus, milles ravimit Symbioflor 2 võrreldi platseeboga, osutus ravim efektiivseks soole ärritussündroomi ravis täiskasvanutel.
English: Symbioflor 2, which contains Escherichia coli bacteria, has been described as a probiotic, which means that it encourages the growth of beneficial organisms (‘flora') in the gut.
Estonian: Escherichia coli baktereid sisaldav ravim Symbioflor 2 on probiootikum ehk ravim, mis toetab kasulike soolebakterite (soolefloora) kasvu.
English: • The company will need to carry out a well-designed study to demonstrate the efficacy and safety of Symbioflor 2 for treating different variants of IBS, as a condition for continuing to market it.
Estonian: • Turustamise jätkamiseks peab ettevõte korraldama hästi kavandatud ülesehitusega uuringu, et tõendada ravimi Symbioflor 2 efektiivsust ja ohutust soole ärritussündroomi eri alavormide korral.
English: • Symbioflor 2 should be used for the treatment of irritable bowel syndrome (IBS) only, and it should no longer be used for treating ‘functional gastrointestinal disorders' or other conditions of the gastrointestinal tract.
Estonian: • Ravimit Symbioflor 2 tohib kasutada ainult soole ärritussündroomi raviks ning mitte enam seedetrakti funktsionaalhäirete või seedetrakti muude häirete korral.
English: You should not use Symbioflor 2 for conditions affecting the gut other than irritable bowel syndrome.
Estonian: Ravimit Symbioflor 2 ei tohi kasutada muude soolehäirete raviks kui soole ärritussündroom.
English: Medicine should no longer be used for other disorders of the gut
Estonian: Teiste soolehäirete raviks ei soovitata ravimit enam kasutada
English: However, the medicine should no longer be used more widely to treat so-called functional gastrointestinal disorders, a group of disorders with a variety of causes that may require different treatment approaches.
Estonian: Samas ei tohi ravimit enam kasutada ulatuslikumal näidustusel, seedetrakti funktsionaalhäirete raviks.
English: A randomised study involving around 300 adults suggested that Symbioflor 2 was effective for treating IBS.
Estonian: Ravimi Symbioflor 2 efektiivsust soole ärritussündroomi ravis tõendati randomiseeritud uuringus, milles osales ligikaudu 300 täiskasvanut.
English: This is then followed by the standard 75 mg dose once a day for at least four weeks (in ST segment elevation myocardial infarction) or for up to 12 months (in non-ST segment elevation syndrome).
Estonian: Seejärel jätkatakse tavalise 75 mg annusega üks kord ööpäevas vähemalt 4 nädalat (ST-segmendi elevatsiooniga infarkti korral) või kuni 12 kuud (ST-segmendi elevatsiooni puudumise korral).
English: The full EPAR for Clopidogrel ratiopharm GmbH can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Clopidogrel ratiopharm GmbH kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: In acute coronary syndrome, Clopidogrel ratiopharm GmbH is used together with aspirin and treatment generally starts with a loading dose of four 75 mg tablets.
Estonian: Akuutse koronaarsündroomi korral kasutatakse Clopidogrel ratiopharm GmbH-d koos aspiriiniga; ravi algab üldiselt küllastusannusega, kus võetakse neli 75 mg tabletti.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Clopidogrel ratiopharm GmbH.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: The European Commission granted a marketing authorisation valid throughout the EU for Clopidogrel ratiopharm GmbH on 28 July 2009.
Estonian: Euroopa Komisjon andis Clopidogrel ratiopharm GmbH müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 28. juulil 2009.
English: Clopidogrel ratiopharm GmbH can be started between seven days and six months after the stroke;
Estonian: Clopidogrel ratiopharm GmbH manustamist tohib alustada 7 päeva kuni 6 kuu jooksul pärast insulti;
English: For more information about treatment with Clopidogrel ratiopharm GmbH, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Clopidogrel ratiopharm GmbH-ga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: The standard dose of Clopidogrel ratiopharm GmbH is one 75 mg tablet once a day.
Estonian: Clopidogrel ratiopharm GmbH tavaannus on üks 75 mg tablett üks kord ööpäevas.
English: Clopidogrel ratiopharm GmbH can be used in patients who are having myocardial infarction with ‘ST segment elevation' (an abnormal reading on the electrocardiogram or ECG) when the doctor thinks that they would benefit from the treatment.
Estonian: Clopidogrel ratiopharm GmbH-d tohib manustada ka patsientidele, kellel on ST-segmendi elevatsiooniga (elektrokardiogrammi ehk EKG teatud ebanormaalne näit) südameinfarkt, kui arst arvab, et ravimil on patsiendile soodne toime.
English: The CHMP concluded that, in accordance with EU requirements, Clopidogrel ratiopharm GmbH has been shown to have comparable quality and to be bioequivalent to Plavix.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud Clopidogrel ratiopharm GmbH võrdväärne kvaliteet ja bioekvivalentsus ravimiga Plavix.
English: This means that Clopidogrel ratiopharm GmbH is similar to a ‘reference medicine' already authorised in the European Union (EU) called Plavix.
Estonian: See tähendab, et Clopidogrel ratiopharm GmbH on sarnane võrdlusravimiga Plavix, millel juba on Euroopa Liidus müügiluba.
English: Because Clopidogrel ratiopharm GmbH is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as the reference medicine's.
Estonian: Et Clopidogrel ratiopharm GmbH on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: Clopidogrel ratiopharm GmbH can be given to the following groups of patients:
Estonian: Clopidogrel ratiopharm GmbH-d tohib kasutada järgmistel patsiendirühmadel:
English: This is a summary of the European public assessment report (EPAR) for Clopidogrel ratiopharm GmbH.
Estonian: See on ravimi Clopidogrel ratiopharm GmbH Euroopa avaliku hindamisaruande kokkuvõte.
English: The Committee recommended that Clopidogrel ratiopharm GmbH be given marketing authorisation.
Estonian: Komitee soovitas anda Clopidogrel ratiopharm GmbH müügiloa.
English: Therefore, the CHMP's view was that, as for Plavix, the benefit outweighs the identified risk.
Estonian: Seetõttu arvas inimravimite komitee, et nagu ka Plavixi korral, ületab Clopidogrel ratiopharm GmbH kasulikkus sellega kaasnevad riskid.
English: Because Clopidogrel ratiopharm GmbH is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Plavix.
Estonian: Et Clopidogrel ratiopharm GmbH on geneeriline ravim, piirdusid patsiendiuuringud katsetega, milles näidati Clopidogrel ratiopharm GmbH bioekvivalentsust võrdlusravimiga Plavix.
English: Clopidogrel ratiopharm GmbH is used in adults to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries).
Estonian: Clopidogrel ratiopharm GmbH-d kasutatakse aterotrombootiliste nähtude (trombide ehk soonesiseste verehüüvete moodustumisest ja arterite lubjastumisest põhjustatud probleemide) ennetamiseks täiskasvanutel.
English: Clopidogrel ratiopharm GmbH is a medicine that contains the active substance clopidogrel.
Estonian: Clopidogrel ratiopharm GmbH on ravim, mis sisaldab toimeainena klopidogreeli.
English: Other information about Clopidogrel ratiopharm GmbH
Estonian: Muu teave Clopidogrel ratiopharm GmbH kohta
English: Clopidogrel ratiopharm GmbH is a ‘generic medicine'.
Estonian: Clopidogrel ratiopharm GmbH on geneeriline ravim.
English: What is Clopidogrel ratiopharm GmbH?
Estonian: Mis on Clopidogrel ratiopharm GmbH?
English: GmbH can be started between a few days and 35 days after the attack;
Estonian: Clopidogrel ratiopharm GmbH manustamist tohib alustada mõne kuni 35 päeva jooksul pärast infarkti;
English: How has Clopidogrel ratiopharm GmbH been studied?
Estonian: Kuidas Clopidogrel ratiopharm GmbH-d uuriti?
English: Why has Clopidogrel ratiopharm GmbH been approved?
Estonian: Miks Clopidogrel ratiopharm GmbH heaks kiideti?
English: • patients who have a condition known as ‘acute coronary syndrome', when it should be given with aspirin (another medicine that prevents blood clots), including patients who have had a stent inserted (a short tube placed in an artery to prevent it closing up).
Estonian: Ravimit tohib anda ka patsientidele, kellele on paigaldatud stent (ahenenud arterit avardav väike toru).
English: How does Clopidogrel ratiopharm GmbH work?
Estonian: Kuidas Clopidogrel ratiopharm GmbH toimib?
English: What is Clopidogrel ratiopharm GmbH used for?
Estonian: Milleks Clopidogrel ratiopharm GmbH-d kasutatakse?
English: How is Clopidogrel ratiopharm GmbH used?
Estonian: Kuidas Clopidogrel ratiopharm GmbH-d kasutatakse?
English: The active substance in Clopidogrel ratiopharm GmbH, clopidogrel, is an inhibitor of platelet aggregation.
Estonian: Clopidogrel ratiopharm GmbH toimeaine klopidogreel on trombotsüütide agregatsiooni (vereliistakute kokkukleepumise) inhibiitor, mis aitab ennetada trombide (soonesiseste verehüüvete) tekkimist.
English: Do not use prophylactically.
Estonian: Mitte kasutada profülaktiliselt.
English: Rabbits: See section 4.4
Estonian: Küülikud: Vt lõik 4.4.
English: 21 days
Estonian: 21 päeva.
English: ATCvet code: QJ01XQ02.
Estonian: ATCvet kood: QJ01XQ02
English: However, the aetiology of ERE still remains unclear.
Estonian: ERE etioloogia on siiani siiski ebaselge.
English: 2 weeks or until signs of disease disappear
Estonian: 2 nädalat või kuni haigustunnused kaovad.
English: Up to 3 weeks
Estonian: Kuni 3 nädalat.
English: Especially in the case of swine dysentery, a targeted early eradication programme of the disease should be considered.
Estonian: Eeskätt sigade düsenteeria puhul tuleks kaaluda sihipärast haiguse varajase elimineerimise programmi.
English: Rabbits: See section “Special warning(s)”
Estonian: Küülikud: Vt lõik „Erihoiatused“
English: For use in individual pigs on farms where only a small number of pigs are to receive the veterinary medicinal product.
Estonian: Kasutamiseks üksikisenditel farmides, kus veterinaarravimit saavad ainult vähesed sead.
English: Consideration should be given to the eradication of infection from the farm.
Estonian: Kaaluda tuleks haiguse täielikku elimineerimist farmist.
English: and Escherichia coli.
Estonian: ja Escherichia coli.
English: In order to obtain the correct dosage, the concentration of Econor has to be adjusted.
Estonian: Et saavutada korrektne annustamine, tuleb Econor'i kontsentratsiooni vastavalt kohandada.
English: Daily dose calculation:
Estonian: Päevase annuse arvutamine:
English: The product should be used as part of a programme including measures aimed at controlling the disease on farm such as biosecurity and husbandry controls.
Estonian: Seda preparaati kasutatakse selliste programmide raames, mille hulka kuuluvad meetmed haigestumuse kontrollimiseks põllumajandusettevõttes, nt bioloogilise ohutuse ja loomakasvatuse kontrollid.
English: However, as absorption, distribution and elimination were very similar in rats, dogs and pigs, it is reasonable to assume that they would be similar in rabbits.
Estonian: Kuna ravimi imendumine, jaotumine ja eritumine on rottidel, koertel ja sigadel väga sarnane, siis on põhjust eeldada, et need võivad olla samasugused ka küülikutel.
English: The product has been shown to be stable to the pelleting process at temperatures of 75 °C.
Estonian: Toode osutus stabiilseks granuleerimisprotsessis temperatuuril 75 °C.
English: 4 weeks
Estonian: 4 nädalat.
English: Rabbits:
Estonian: Küülikud:
English: Once opened use within 6 months.
Estonian: Pärast pakendi avamist kasutada 6 kuu jooksul.
English: Shelf life after first opening the immediate packaging: use within 6 months.
Estonian: Kõlblikkusaeg pärast vahetu pakendi esmast avamist: kasutada 6 kuu jooksul.